Hypertension and coronary artery disease are the most frequent causes of chronic heart failure. Activation of neurohumoral mechanisms including vasoconstriction and sodium retaining mechanisms opposed by vasorelaxant and natriuretic factors are involved in the pathophysiology of heart failure. 1 Diastolic heart failure is characterised by symptoms of heart failure and increased filling pressure of the left ventricle without systolic dysfunction. In patients with hypertension, diastolic dysfunction is caused by decreased ventricular relaxation and increased ventricular stiffness. Moreover, hypertrophy makes ventricular filling slower than normal. Background and rationale
Introduction
Hypertension and coronary artery disease are the most frequent causes of chronic heart failure. Activation of neurohumoral mechanisms including vasoconstriction and sodium retaining mechanisms opposed by vasorelaxant and natriuretic factors are involved in the pathophysiology of heart failure. 1 Diastolic heart failure is characterised by symptoms of heart failure and increased filling pressure of the left ventricle without systolic dysfunction. In patients with hypertension, diastolic dysfunction is caused by decreased ventricular relaxation and increased ventricular stiffness. Moreover, hypertrophy makes ventricular filling slower than normal. 2 
Background and rationale
Atrial natriuretic peptide (ANP) is a natriuretic, diuretic and vasorelaxant peptide released from cardiac atria in response to atrial distension. It circulates as a 28-amino-acid active hormone and an inactive amino terminal part called NT-proANP. The main ventricular natriuretic peptide is B-type natriuretic peptide (BNP) which circulates as a 32-Correspondence: Paavo Uusimaa MD, PhD, Department of Internal Medicine, University of Oulu, Kajaanintie 50, 90220 Oulu, Finland. E-mail: paavo.uusimaaȰoulu.fi amino-acid active hormone and an inactive amino terminal part called NT-proBNP. 3, 4 Studies on genetically manipulated rodents have shown the importance of natriuretic peptides in maintaining normal blood pressure. The cardiac natriuretic peptide system is activated during cardiac hypertrophy and also in congestive heart failure in relation to systolic dysfunction. 4 In the general population circulating NT-proANP is an independent predictor of left ventricular (LV) hypertrophy, 5 but the role of natriuretic peptides in diastolic heart failure is unclear. Natriuretic peptide gene expression is activated in patients with hypertrophic cardiomyopathy and aortic stenosis 6, 7 and their plasma concentrations correlate with diastolic parameters of the left ventricle. [8] [9] [10] [11] [12] [13] Endothelin-1 (ET-1) is a 21-amino-acid vasoconstrictor peptide secreted mainly by the vascular endothelium. Its plasma concentration is increased in patients with heart failure in relation to severity of the disease.
14 ET-1 is also involved in the pathophysiology of hypertension, development of cardiomyocyte hypertrophy and also remodelling of the cardiac fibrous tissue. 15 Adrenomedullin (ADM) is a newly discovered 52-amino-acid peptide with vasorelaxant, inotropic, natriuretic and diuretic activity. Its plasma concentration is increased in patients with essential hypertension 16 and heart failure 17 and its gene expression in the heart is stimulated by acute pressure overload. 18 There are no studies on the relationships between ET-1 or ADM and diastolic properties of the left ventricle. Cardiac remodelling is associated with changes in myocardial connective tissue. 19 Moreover, LV stiffness is correlated with changes in collagen structure. 20 Since the aminoterminal propeptide of type I procollagen (intact PINP), the carboxyterminal propeptide of type I procollagen (PICP) and the aminoterminal propeptide of type III procollagen (PIIINP) are liberated during collagen biosynthesis, it is possible to use them as markers of this process. 21 PIIINP reflects the turnover of soft tissue collagen, whereas intact PINP and PICP reflect mainly the turnover of bone collagen. It has been shown previously that serum PIIINP concentration reflects repair after infarction. 22, 23 Similarly, serum PINP and PIIINP concentrations are increased in patients with hypertension in relation to anatomical and functional alterations. 24 Therefore, measuring serum concentrations of procollagen propeptides may have a role in diagnosing cardiac fibrosis.
Objectives
The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) compares the effects of amlodipine (combined with perindopril if necessary) and atenolol (combined with bendrofluazide if necessary) on fatal coronary artery disease events and non-fatal myocardial infarction in high risk patients with hypertension. The objectives of the present substudy are: (1) to clarify the role of vasoactive peptides and cardiac fibrosis in the pathophysiology of LV hypertrophy and diastolic heart failure in patients with hypertension, (2) to evaluate the roles of plasma vasoactive peptides and serum procollagen propeptides in the diagnostics of these processes, and (3) to study the effect of two treatment arms on cardiac function, neurohumoral activation and cardiac fibrosis.
Study methods
The protocol of the main study is published elsewhere in this issue. The present sub-study is performed at the Oulu Deaconess Institute. The protocol was approved by the ethical committee of the institute and a written informed consent was obtained from all the patients before the study. A total of 99 patients, 83 males and 16 females, screened to the ASCOT-study in Oulu and its surroundings were recruited into the sub-study. Clinical characteristics of the patients are shown in Table 1 . Systolic blood pressure of the patients at the screening visit was 170.1 ± 2.0 mm Hg and diastolic blood pressure 99.5 ± 1.2 mm Hg (mean ± s.e.m.).
According to the sub-study protocol echocardiography is performed by three experienced cardiologists (PU, AY and KP) using a Toshiba PowerVision before randomisation, at 2.5 years and at the end of the study. The measurements include following The total number of the patients in the sub-study is 99 patients. 2 isovolumic relaxation time, E-wave max , Awave max , E/A ratio expressed in terms of the peak velocities, rate of deceleration of flow and velocitytime integrals.
Samples for measuring plasma concentrations of vasoactive peptides and serum concentrations of procollagen propeptides are taken immediately before echocardiography after 10 min sitting. Samples for vasoactive peptides are taken into chilled tubes containing EDTA and those for procollagen propeptides into tubes at room temperature. The plasma and sera are separated and stored at −70°C until analysed. Concentrations of ANP, 26 NTproANP, ET-1 27 and adrenomedullin 18 will be measured by radioimmunoassays and BNP and NTproBNP according to the same protocol as ANP and NT-proANP, respectively. The concentrations of PII-INP, PICP and intact PINP will be analysed with commercially available radioimmunoassays (Orion Diagnostica, Oulunsalo, Finland). [28] [29] [30] Conventional statistical methods including Student's t-test, analysis of variance for repeated measurements and regression analysis are used in the study.
Discussion
Hypertension is an important cause of LV hypertrophy often accompanied by diastolic dysfunction. The ASCOT trial compares the effects of amlodipine and atenolol on fatal coronary artery disease events and non-fatal myocardial infarction in high risk patients with hypertension. The present sub-study is primarily planned to give information on the relationships of diastolic heart failure, development of cardiac fibrosis and changes in circulating vasoactive peptides in patients with hypertension. According to the main study protocol the effects of the two treatments arms on these parameters are also studied. The role of neurohumoral mechanisms in systolic dysfunction has been evaluated in numerous studies during recent years, 1 but the relationships between vasoactive peptides and diastolic parameters in hypertension have been evaluated only for ANP 8 and BNP. 12 Moreover, there is only one study evaluating the role of cardiac collagen metabolism in patients with hypertension. 24 The patient material of the ASCOT study is very suitable for studying the pathophysiology of cardiac hypertrophy and diastolic heart failure due to the study design. In contrast to some previous studies on vasoactive peptides which have included patients with various aetiologies of dysfunction and also patients with systolic dysfunction, [9] [10] [11] 13 the homogeneity of the patient material is a major concern in the present study. It is ascertained by excluding patients with angina pectoris and previous myocardial infarction from the study. Contribution of systolic dysfunction or related valvular diseases can be evaluated by echocardiography. Moreover, patients with significant renal or hepatic failure are also excluded from the main study which prevents the interference of these conditions on the concentrations of markers being studied.
Echocardiography using standardised techniques has been shown to be a more sensitive tool than electrocardiography for the detection of LV hypertrophy. However, there are problems in variability and reliability of this technique in detecting changes in LV mass. 31, 32 During recent years Doppler echocardiographic measurement of LV filling pattern has become a useful method for assessing diastolic performance of the left ventricle. 2 The biochemical methods used in the present study for vasoactive peptides 18, 26, 27, 33 and procollagen propeptides [28] [29] [30] are well documented and developed in our laboratories and those for procollagen propeptides also commercially available (Orion Diagnostica, Oulunsalo, Finland). In addition to historical controls for these parameters, age-and sex-matched controls will be acquired.
The present study was primarily planned to give information on the pathophysiological aspects of hypertension and especially to study correlations between parameters of LV function, collagen propeptides and vasoactive peptides. It is difficult to determine the number of patients needed in a follow-up study to observe differences between two treatment arms and to make exact power calculations. Therefore, the sample size was limited to 100 patients for practical reasons. This should be enough, since previously small studies investigating pathophysiology of hypertension and LV hypertrophy have been estimated to require 40-60 patients per treatment group. 34 In conclusion, the patient material of the ASCOT study offers a suitable follow-up material for studying both neurohumoral changes and development of Journal of Human Hypertension cardiac fibrosis in patients with hypertension in relation to LV systolic and diastolic function.
